Search results
Results from the WOW.Com Content Network
Carboplatin, sold under the brand name Paraplatin among others, is a chemotherapy medication used to treat a number of forms of cancer. [3] ... Mechanism of action
This mechanism leads to specific patterns of damage in DNA, which can kill cancer cells but can also increase the risk of secondary tumors developing. [6] Platinum-based antineoplastic agents are sometimes described as "alkylating-like" due to similar effects as alkylating antineoplastic agents, although they do not have an alkyl group. [7]
Carboplatin: IV: Reacts with DNA, inducing apoptosis, non-cell cycle specific. Ovarian cancer, lung cancer and squamous cell head and neck cancer: Myelosuppression, nausea and vomiting (30-90%), peripheral neuropathy, ototoxicity, anaphylaxis, acute kidney failure (rare), haemolytic uraemic syndrome (rare) and loss of vision (rare). Cisplatin: IV
Some alkylating agents are active under conditions present in cells; and the same mechanism that makes them toxic allows them to be used as anti-cancer drugs. They stop tumor growth by crosslinking guanine nucleobases in DNA double-helix strands, directly attacking DNA. This makes the strands unable to uncoil and separate.
Pemetrexed is also recommended in combination with carboplatin and pembrolizumab for the first-line treatment of advanced non-small cell lung cancer. [12] [13] However, the relative efficacy or toxicity of pemetrexed-cisplatin versus pemetrexed-carboplatin has not been established beyond what is generally thought about cisplatin or carboplatin doublet drug therapy.
At present, reversion-driven HR restoration has been established as the most common resistance mechanism. Reversion-driven HR restoration is the result of secondary mutation events within BRCA1, BRCA2 , or other HR-related factors, which restore protein function and, thus, HR proficiency.
Image source: The Motley Fool. AbbVie (NYSE: ABBV) Q4 2024 Earnings Call Jan 31, 2025, 9:00 a.m. ET. Contents: Prepared Remarks. Questions and Answers. Call ...
The inhibitor binds to the zinc at the active center of the enzyme, thereby blocking its activity. Other inhibitor mechanisms are possible. [1] α2-Macroglobulin (α2M) is a protease inhibitor which inhibits activated MMPs. α2M and MMP form a complex which is able to inactivate the MMP. [9]